What Your Gut Has Been Trying to Tell You — About Your Weight and Your Health

Nobody is telling you this.

Not your doctor. Not the diet industry. Not the commercials for Ozempic and Wegovy that are everywhere right now. Nobody is sitting down with you and explaining the actual biology of why weight loss has been so hard — why you could do everything right and still not win.

That changes today.

Because once you understand what’s been working against you at the microbial level, two things happen. First, you stop blaming yourself. Second, you finally have a map.

At the center of that conversation is the connection between gut health and weight loss — a link the research has been building for years but that almost nobody is explaining in plain language.

The Conversation Everyone Is Having — And What’s Missing From It

The GLP-1 drug boom is real. Semaglutide, tirzepatide, Ozempic, Mounjaro, Wegovy — these medications are genuinely effective for many people and they represent a legitimate advance in how medicine thinks about obesity. I’m not here to dismiss them.

But the conversation stops too soon. Everyone is talking about what these drugs do. Nobody is asking why the body stopped doing it naturally in the first place.

GLP-1 and GIP are hormones your gut is designed to produce on its own. They regulate insulin, suppress appetite, create satiety, slow digestion, and signal your brain that you’ve had enough. That system exists in you right now. The question worth asking — the question almost no one is asking — is whether that system is working, and if not, why not.

The answer, for a significant number of people struggling with weight, lives in the gut.

Your gut is home to roughly 38 trillion microorganisms — bacteria, fungi, and viruses — that collectively function as a metabolic organ.[1,2] They influence how many calories you extract from food, how much fat you store, how your immune system behaves, how your hunger hormones signal, and how sensitive your cells are to insulin.

When that ecosystem is balanced, it supports a lean, efficient metabolism. When it shifts into what researchers call dysbiosis — a state of microbial imbalance — your biology can begin working against you in ways that have nothing to do with willpower.[3,4] We covered the full science of how this works in The Ecosystem Inside You — worth reading if you want the deeper foundation before continuing.

Here is what that actually looks like, mechanically. Research has identified four distinct pathways through which a disrupted gut microbiome may contribute to obesity. Understanding all four is why this conversation matters.

1. Your gut bacteria may be extracting more calories from your food than someone else’s.

A healthy gut microbiome is dominated by two major bacterial families: Firmicutes and Bacteroidetes. Multiple studies have found that in people with obesity, the ratio between these families shifts — Firmicutes tend to rise and Bacteroidetes tend to fall — though this finding is not universal across all studies.[2,4,9,10,11]

Why does that matter? Firmicutes are extraordinarily efficient at harvesting energy from food. When they dominate, your body may extract more calories from the same meal than a leaner person eating identically. You are not imagining it. You are not necessarily eating more than you think. Your gut may be running a different metabolic program — one that was never explained to you.

Bacteroidetes depletion may compound this further. In animal studies, these bacteria have been shown to stimulate a protein called FIAF — fasting-induced adipocyte factor — which acts as a biological brake on fat storage. When Bacteroidetes decline, FIAF declines with them. An enzyme called lipoprotein lipase then runs unchecked, and the body shifts more aggressively into fat storage mode.[2] While this mechanism is well-established in animal models, research is still working to confirm the full extent of this effect in humans.

2. Inflammation in your gut may be driving fat storage and insulin resistance throughout your entire body.

Certain bacteria — both pathogenic Firmicutes members and gram-negative bacteria like Proteobacteria and Fusobacteria — produce a toxin called lipopolysaccharide, or LPS. In a healthy gut, the intestinal barrier keeps LPS contained. In a compromised gut, that barrier weakens, and LPS can flood into circulation.[5,6]

Once in the bloodstream, LPS triggers a cascade — binding to immune receptors, activating NF-kB, releasing pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6.[5,6] That systemic inflammation can drive insulin resistance, which drives fat accumulation, which drives more inflammation. It is a loop with no natural exit point unless the gut is addressed directly.

This is chronic low-grade inflammation. It doesn’t present like an acute infection. It is associated with metabolic dysfunction that can manifest as fatigue, difficulty losing weight, and other symptoms that are hard to pin down.

3. Your lymphatic system — your body’s waste removal network — may be compromised.

This is the mechanism almost no one talks about. Your GI lymphatic system runs alongside your digestive tract and performs two critical functions: it removes metabolic waste from cells and it transports dietary fats through specialized capillaries called lacteals in the intestinal villi.[7]

When LPS damages the intestinal lining, it doesn’t just enter the bloodstream — research suggests it can also enter the lymphatic system, where it may be transported alongside dietary fats into systemic circulation. That LPS-laden lymph can then reach the liver and adipose tissue, potentially seeding inflammation in both.[7,8]

Obesity and lymphatic dysfunction appear to be bidirectional — each may make the other worse.[7] This is one reason why so many people carry visceral fat that does not respond well to diet and exercise alone. The drainage system itself may be part of the problem.

4. Your hunger signals may be generated by altered nerve signaling, not genuine need.

The enteric nervous system — the network of nerves lining your digestive tract — communicates constantly with your brain. It is the physical infrastructure of the gut-brain axis. Research suggests that when chronic gut inflammation and poor lymphatic circulation affect these nerves, they can begin generating distorted signals — including appetite cues that don’t reflect actual hunger or nutritional need.[2,5]

This is not a lack of self-control. This may be an altered neural signaling system sending misleading signals. And it connects to an emerging question in the research: whether GLP-1 and GIP — the appetite-regulating hormones that weight loss drugs mimic — function as effectively in someone with significant dysbiosis. The signal may be broadcast into a system that has been conditioned to misread it.

Here is something that connects the dots in a way most people never expect: the same LPS-driven inflammation we just described doesn’t limit itself to fat storage and insulin resistance. It reaches your joints, your muscles, and your spine.

Researchers have identified what they now call the “gut-joint axis” — a pathway through which gut dysbiosis contributes to joint inflammation and degeneration.[17,18] The mechanism is the same one we covered above: a compromised gut barrier allows LPS into circulation, where it activates TLR4 receptors and triggers the release of TNF-α, IL-1β, and IL-6. In the joints, that inflammatory cascade can promote synovitis and accelerate cartilage breakdown. A 2016 review in Nature Reviews Rheumatology proposed that LPS may be “a major hidden risk factor that provides a unifying mechanism to explain the association between obesity, metabolic syndrome and osteoarthritis.”[15] Multiple systematic reviews have since confirmed preliminary evidence supporting this gut-joint connection, showing that the same Firmicutes/Bacteroidetes imbalance and increased intestinal permeability seen in obesity are also associated with osteoarthritis severity.[16,18]

The research extends beyond the joints. A growing body of evidence points to a “gut-spine axis” as well — a connection between gut microbiome composition and spinal degenerative conditions including intervertebral disc degeneration and chronic low back pain.[19] A 2026 study in The Journal of Pain found that patients with chronic low back pain showed a distinct pattern of gut dysbiosis characterized by reduced butyrate-producing bacteria and increased pro-inflammatory species — a microbial signature the authors described as “proinflammatory/pronociceptive.”[20] Mendelian randomization studies have further supported a causal relationship between specific gut microbial taxa and low back pain risk.

And here is where it gets personal for our practice. Human experimental studies have directly demonstrated that LPS-induced systemic inflammation lowers pressure pain thresholds across multiple muscle groups — including the erector spinae, the muscles that run along your spine.[21,22,23] In pooled data from three randomized controlled trials, healthy volunteers who received even low-dose LPS showed significantly increased musculoskeletal pain sensitivity, with the effect correlated to TNF-α levels.

This is why, in our clinic, a patient who comes in with chronic musculoskeletal pain, stubborn postural dysfunction, or joint stiffness that doesn’t fully resolve with structural work alone gets a broader conversation. Because if the same inflammatory process is driving both your weight challenges and your pain — and the research increasingly suggests it can — then addressing the gut isn’t a detour from musculoskeletal care. It may be the missing piece of it.

That’s the advantage of working with practitioners who look at the whole system. A chiropractor evaluating your posture, your movement patterns, and your pain is already paying attention to how your body is functioning as an integrated unit. Adding gut health to that assessment isn’t a stretch — it’s a natural extension of the same question we’re already asking: why isn’t your body recovering the way it should?

Here is what the research is beginning to show, and what is not yet part of the mainstream conversation:

Animal studies have demonstrated that chronic LPS exposure from gut dysbiosis can initially stimulate GLP-1 and GIP secretion — the gut is trying to compensate. But over time, that same LPS-driven inflammatory environment may create what researchers have called incretin resistance — a blunting of the enteric neurons that should respond to GLP-1 signaling. In these animal models, the natural appetite suppression, insulin regulation, and satiety signaling these hormones provide begins to fail.[10,11]

It is important to note that this research has been conducted primarily in mice, and the clinical translation to humans — particularly to people taking GLP-1 receptor agonist drugs at pharmacological doses — is not yet established. GLP-1 medications like semaglutide work at doses far higher than endogenous GLP-1 and act through multiple mechanisms, including direct effects on the brain. So the animal findings do not mean these drugs won’t work in people with dysbiosis.

However, the question is worth asking: could the gut environment a person brings to GLP-1 therapy influence how well that therapy works, or how long it is needed? Early research suggests this is plausible, and some researchers have proposed that integrating microbiome assessment with metabolic therapies may help explain variability in treatment responses.

This is why I believe gut health deserves attention for anyone on or considering GLP-1 therapy. Not instead of the medication — and this is not medical advice about any specific drug, which is the domain of your prescribing physician. But as a complementary consideration, because the gut environment may influence the foundation these therapies are working with.

A gut that supports healthy weight has a few non-negotiable features: high microbial diversity, Bacteroidetes holding their own against Firmicutes, robust populations of keystone protective species, strong short-chain fatty acid production, and an intact mucosal barrier keeping LPS where it belongs.[3,4]

The keystone species matter enormously. Akkermansia muciniphila maintains the mucosal lining — the first line of gut barrier defense. Faecalibacterium prausnitzii is the primary butyrate producer, the metabolite that feeds gut lining cells and keeps inflammation in check. Bifidobacterium longum and Bifidobacterium adolescentis modulate immune function and inhibit the NF-kB inflammatory pathway directly.[1,2] When these are depleted, the entire system becomes vulnerable.

Clinically, I’m also looking at the stress load and sleep quality — because both have been shown to alter microbial composition. Chronic stress can increase intestinal permeability and change neurotransmitter production. Poor sleep can worsen dysbiosis, and a disrupted microbiome can worsen sleep.[1] These loops run in parallel with the metabolic dysfunction and benefit from being addressed together.

You didn’t fail at weight loss because you lacked discipline. You may have been fighting a biological system that was working against you in multiple simultaneous ways — extracting more calories from your food, generating systemic inflammation, compromising your lymphatic system, and sending you misleading hunger signals from altered nerve pathways. And that same inflammation may have been contributing to your joint pain, your back stiffness, and the musculoskeletal issues that never quite resolve. No one explained any of it to you.

That is what we do differently here.

Understanding your gut is not a luxury add-on to a weight loss plan or a pain management plan. For many people it may be central to both — with or without pharmaceutical support. And for those who do need GLP-1 therapy, a healthier gut may give that therapy its best possible foundation, and potentially, over time, reduce the need for it.

That’s the goal. Independence. Understanding your own biology well enough to work with it instead of against it.

You always had a chance. You just needed the right information. Gut health and weight loss are not separate conversations. They are the same conversation.

References

1. Lovelle S. The Weight Loss Drug Boom and the Pivotal Role of the Gut Microbiome in Metabolic Dysfunction. Clinical presentation; Balanced Performance/Microbiome Labs; 2023.
2. Wei Laboratories. Weight Loss Protocol (Document 1125-04). Wei Laboratories, Inc.; Los Altos, CA.
3. Breton J, Galmiche M, Déchelotte P. Dysbiotic Gut Bacteria in Obesity: An Overview of the Metabolic Mechanisms and Therapeutic Perspectives of Next-Generation Probiotics. Microorganisms. 2022;10(2):452. doi: 10.3390/microorganisms10020452.
4. Amabebe E, Robert FO, Agbalalah T, Orubu ESF. Microbial dysbiosis-induced obesity: role of gut microbiota in homoeostasis of energy metabolism. Br J Nutr. 2020;123(10):1127-1137. doi: 10.1017/S0007114520000380.
5. Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health and disease. Cell Res. 2020;30:492–506. doi: 10.1038/s41422-020-0332-7.
6. Yang-Jensen SK, Nägele NS, Jensen BAH. From Gut to Blood: Barrier Dysfunction as a Driver of Systemic Low-Grade Inflammation in Cardiometabolic Disease. Am J Physiol Cell Physiol. 2025. doi: 10.1152/ajpcell.00704.2025.
7. Cao E, Watt MJ, Nowell CJ, et al. Mesenteric lymphatic dysfunction promotes insulin resistance and represents a potential treatment target in obesity. Nat Metab. 2021;3:1175–1188. doi: 10.1038/s42255-021-00457-w.
8. Solari E, Marcozzi C, Negrini D, Moriondo A. Interplay between Gut Lymphatic Vessels and Microbiota. Cells. 2021;10(10):2584. doi: 10.3390/cells10102584.
9. Crovesy L, Masterson D, Rosado EL. Profile of the gut microbiota of adults with obesity: a systematic review. Eur J Clin Nutr. 2020;74(9):1251-1262. doi: 10.1038/s41430-020-0607-6.
10. Zeng Y, Wu Y, Zhang Q, Xiao X. Crosstalk between glucagon-like peptide 1 and gut microbiota in metabolic diseases. mBio. 2024;15(1). doi: 10.1128/mbio.02032-23.
11. Grasset E, Puel A, Charpentier J, et al. A Specific Gut Microbiota Dysbiosis of Type 2 Diabetic Mice Induces GLP-1 Resistance through an Enteric NO-Dependent and Gut-Brain Axis Mechanism. Cell Metab. 2017;25(5):1075-1090. doi: 10.1016/j.cmet.2017.04.013.
12. Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984.
13. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216.
14. McFarlin BK, et al. Prebiotic/probiotic Supplementation Resulted in Reduced Visceral Fat and mRNA Expression Associated with Adipose Tissue Inflammation, Systemic Inflammation, and Chronic Disease Risk. Genes Nutr. 2022;17:15. doi: 10.1186/s12263-022-00718-7.
15. Huang Z, Kraus VB. Does lipopolysaccharide-mediated inflammation have a role in OA? Nat Rev Rheumatol. 2016;12(2):123-9. doi: 10.1038/nrrheum.2015.158.
16. Chisari E, Wouthuyzen-Bakker M, Friedrich AW, Parvizi J. The relation between the gut microbiome and osteoarthritis: A systematic review of literature. PLoS One. 2021;16(12):e0261353. doi: 10.1371/journal.pone.0261353.
17. Wei J, Zhang Y, Xie C, Lei G, Zeng C. The gut-joint axis in osteoarthritis. Nat Rev Rheumatol. 2026. doi: 10.1038/s41584-026-01378-2.
18. Liu S, Li G, Xu H, et al. “Cross-talk” between gut microbiome dysbiosis and osteoarthritis progression: a systematic review. Front Immunol. 2023;14:1150572. doi: 10.3389/fimmu.2023.1150572.
19. Morimoto T, Kobayashi T, Kakiuchi T, et al. Gut-spine axis: a possible correlation between gut microbiota and spinal degenerative diseases. Front Microbiol. 2023;14:1290858. doi: 10.3389/fmicb.2023.1290858.
20. Saravanan A, Bai J, Bajaj P, et al. Evidence for a shift towards a proinflammatory/pronociceptive signature of gut dysbiosis in patients with axial chronic low back pain. J Pain. 2026;44:106271. doi: 10.1016/j.jpain.2026.106271.
21. Benson S, Engler H, Wegner A, Schedlowski M, Elsenbruch S. Elucidating vulnerability to inflammation-induced hyperalgesia: predictors of increased musculoskeletal pain sensitivity during experimental endotoxemia. Brain Behav Immun. 2020;88:302-307. doi: 10.1016/j.bbi.2020.06.022.
22. Wegner A, Elsenbruch S, Rebernik L, et al. Inflammation-induced pain sensitization in men and women: does sex matter in experimental endotoxemia? Pain. 2015;156(10):1954-1964. doi: 10.1097/j.pain.0000000000000256.
23. de Goeij M, van Eijk LT, Vanelderen P, et al. Systemic inflammation decreases pain threshold in humans in vivo. PLoS One. 2013;8(12):e84159. doi: 10.1371/journal.pone.0084159.

---

Dr. Anish Bajaj, DC is the founder of Well Rooted Health (Westfield, NJ) and Well Rooted Chiropractic (NYC). His clinical focus spans posture and neuromuscular health, nutrition, cognitive function, and sleep. This blog is for educational purposes and does not constitute medical advice. Consult your provider before making changes to your health regimen.